The arrival of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable excitement within the weight loss community. This groundbreaking dual GIP and GLP-1 receptor medication appears to offer notable improvements in weight shedding compared to existing therapies. Preliminary clinical trials have demonstrated substantial declines in